Caris Life Sciences Inc當前公司基本面數據相對非常健康,增長潛力很大。當前估值低估,在醫療設備與耗材行業排名65/208位。機構持股佔比非常高,近一個月多位分析師給出公司評級為買入。最高目標價38.11。中期看,股價處於平穩狀態。近一個月,市場表現很強,技術面和基本面綜合得分較高,很強的走勢得到基本面和技術面的印證。目前股價在壓力位和支撐位之間,可以做區間波段操作。
Caris Life Sciences Inc評分
相關信息
行業排名
65 / 208
全市場排名
162 / 4582
所屬行業
醫療設備與耗材
壓力支撐
由於公司未披露,未能獲取相關數據
多維評測
本期評分
上期評分
分析師目標
基於
9
分析師
買入
評級
38.111
目標均價
+34.38%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議
Caris Life Sciences Inc亮點
亮點風險
Caris Life Sciences Inc. is a patient-centric, next-generation artificial intelligence tech bio company and precision medicine provider. The Company develops and commercializes solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. Its entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets. Its platform is purpose-built to leverage the convergence of next-generation sequencing (NGS), artificial intelligence (AI) and machine learning (ML) technologies, and high-performance computing. Its purpose-built, proprietary multi-omic profiling solutions capture and analyze molecular information from tissue and blood in a comprehensive manner. Its services for biopharma companies include prospective and retrospective profiling services, and companion diagnostics development.
Caris Life Sciences Inc. is a patient-centric, next-generation artificial intelligence tech bio company and precision medicine provider. The Company develops and commercializes solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. Its entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets. Its platform is purpose-built to leverage the convergence of next-generation sequencing (NGS), artificial intelligence (AI) and machine learning (ML) technologies, and high-performance computing. Its purpose-built, proprietary multi-omic profiling solutions capture and analyze molecular information from tissue and blood in a comprehensive manner. Its services for biopharma companies include prospective and retrospective profiling services, and companion diagnostics development.
公司代碼CAI
公司Caris Life Sciences Inc
CEOHalbert (David Dean)
網址https://www.carislifesciences.com/
常見問題
Caris Life Sciences Inc(CAI)的當前股價是多少?
Caris Life Sciences Inc(CAI)的當前股價是 27.940。
Caris Life Sciences Inc 的股票代碼是什麼?
Caris Life Sciences Inc的股票代碼是CAI。
Caris Life Sciences Inc股票的52週最高點是多少?
Caris Life Sciences Inc股票的52週最高點是42.500。
Caris Life Sciences Inc股票的52週最低點是多少?
Caris Life Sciences Inc股票的52週最低點是22.860。
Caris Life Sciences Inc的市值是多少?
Caris Life Sciences Inc的市值是7.88B。
Caris Life Sciences Inc的淨利潤是多少?
Caris Life Sciences Inc的淨利潤為-378.26M。
現在Caris Life Sciences Inc(CAI)的股票是買入、持有還是賣出?
根據分析師評級,Caris Life Sciences Inc(CAI)的總體評級為買入,目標價格為38.111。
Caris Life Sciences Inc(CAI)股票的每股收益(EPS TTM)是多少
Caris Life Sciences Inc(CAI)股票的每股收益(EPS TTM)是-5.049。